• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

网络荟萃分析的国家指南比较。

A Comparison of National Guidelines for Network Meta-Analysis.

机构信息

Amaris Health Economics & Market Access, London, England, UK.

ICON Plc, Vancouver, British Columbia, Canada.

出版信息

Value Health. 2019 Oct;22(10):1178-1186. doi: 10.1016/j.jval.2019.05.013. Epub 2019 Aug 23.

DOI:10.1016/j.jval.2019.05.013
PMID:31563261
Abstract

BACKGROUND

Network meta-analysis (NMA) techniques allow the comparison of a complete set of interventions for patient groups. These meta-analysis techniques may be the only source of evidence to underpin estimates of comparative efficacy. Reimbursement agencies around the world are increasingly reliant upon meta-analysis techniques and assess their design and conduct with growing sophistication.

OBJECTIVE

Our objective is to create a superset of requirements collated from available national guidelines for the conduct of network meta-analysis such that a single analysis may be conducted to satisfy all reimbursement bodies that have specified requirements in sufficient detail.

METHODS

Published and draft guidelines documents from reimbursement bodies and health technology appraisal agencies were examined for their stipulations as to the conduct and design of network meta-analysis and measures to be taken to reduce bias and increase validity.

RESULTS

Guidelines from 41 countries were reviewed, yielding a sample size of 13 countries' guideline documents: Australia, Belgium, Canada, China, Ireland, England and Wales, France, Germany, Scotland, South Africa, South Korea, Spain, Thailand, and a guideline document from the European Network of Health Technology Assessment, which contained explicit recommendations or requirements for conduct of NMA.

CONCLUSION

This study expands the range of previous work that reviewed the guidelines for the use of indirect evidence from multiple national jurisdictions. These aggregate guidelines do not include requirements that are mutually prohibitive. It is possible to perform a single NMA for submission to an expanded list of national jurisdictions.

摘要

背景

网络荟萃分析(NMA)技术允许对一组完整的患者群体干预措施进行比较。这些荟萃分析技术可能是支持比较疗效估计的唯一证据来源。全球范围内的报销机构越来越依赖荟萃分析技术,并越来越复杂地评估其设计和实施。

目的

我们的目标是创建一套从现有的国家指南中收集的要求,以便进行单一分析,以满足所有有具体要求且规定足够详细的报销机构。

方法

检查了来自报销机构和卫生技术评估机构的已发表和草案指南文件,以了解其对网络荟萃分析的实施和设计的规定,以及为减少偏差和提高有效性而采取的措施。

结果

审查了 41 个国家的指南,得出了 13 个国家指南文件的样本量:澳大利亚、比利时、加拿大、中国、爱尔兰、英格兰和威尔士、法国、德国、苏格兰、南非、韩国、西班牙、泰国,以及一份来自欧洲卫生技术评估网络的指南文件,其中包含了对 NMA 进行的明确建议或要求。

结论

本研究扩展了之前从多个国家司法管辖区审查间接证据使用指南的工作范围。这些综合指南不包括相互禁止的要求。有可能对提交给更多国家司法管辖区的单一 NMA 进行。

相似文献

1
A Comparison of National Guidelines for Network Meta-Analysis.网络荟萃分析的国家指南比较。
Value Health. 2019 Oct;22(10):1178-1186. doi: 10.1016/j.jval.2019.05.013. Epub 2019 Aug 23.
2
A comparison of national guidelines for network meta-analysis.各国网络荟萃分析指南比较。
Value Health. 2014 Jul;17(5):642-54. doi: 10.1016/j.jval.2014.06.001.
3
Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.卫生技术评估(HTA)案例研究:影响澳大利亚、加拿大、英格兰和苏格兰卫生技术评估报销建议分歧的因素
Value Health. 2017 Mar;20(3):320-328. doi: 10.1016/j.jval.2016.10.014. Epub 2016 Dec 22.
4
Clinical guidelines and payer policies on fusion for the treatment of chronic low back pain.临床指南和支付方政策对慢性下腰痛融合治疗的影响。
Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S144-63. doi: 10.1097/BRS.0b013e31822ef5b4.
5
6
Reimbursement agency requirements for health related quality-of-life data: a case study.报销机构对健康相关生活质量数据的要求:案例研究。
Expert Rev Pharmacoecon Outcomes Res. 2009 Dec;9(6):527-37. doi: 10.1586/erp.09.62.
7
Methods and characteristics of published network meta-analyses using individual patient data: protocol for a scoping review.使用个体患者数据的已发表网络荟萃分析的方法和特征:一项范围综述方案
BMJ Open. 2015 Apr 29;5(4):e007103. doi: 10.1136/bmjopen-2014-007103.
8
A comparison of pharmaceutical reimbursement agencies' processes and methods in France and Scotland.法国和苏格兰药品报销机构的流程和方法比较。
Int J Technol Assess Health Care. 2012 Apr;28(2):187-94. doi: 10.1017/S0266462312000104.
9
The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.ISPOR 成本效益研究质量改进良好实践工作组报告。
Value Health. 2009 Nov-Dec;12(8):1086-99. doi: 10.1111/j.1524-4733.2009.00605.x. Epub 2009 Sep 10.
10
Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.在欧洲国家,用于定价和报销决策的肿瘤药物的相对有效性评估。
Ann Oncol. 2016 Sep;27(9):1768-75. doi: 10.1093/annonc/mdw233. Epub 2016 Jun 20.

引用本文的文献

1
Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis.1.5%鲁索替尼乳膏与全身用药治疗中度特应性皮炎的网状Meta分析
Dermatol Ther (Heidelb). 2025 Sep 4. doi: 10.1007/s13555-025-01503-1.
2
Selection of indirect treatment comparisons for health technology assessments: a practical guide for health economics and outcomes research scientists and clinicians.卫生技术评估中间接治疗比较的选择:卫生经济学与结果研究科学家及临床医生实用指南
BMJ Open. 2025 Mar 25;15(3):e091961. doi: 10.1136/bmjopen-2024-091961.
3
Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis.
11种不同剂量钠-葡萄糖协同转运蛋白2抑制剂用于二甲双胍控制不佳的2型糖尿病患者的疗效和安全性:一项贝叶斯网络荟萃分析
BMJ Open. 2025 Feb 26;15(2):e088687. doi: 10.1136/bmjopen-2024-088687.
4
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.比较屈昔多巴、大麻二酚和芬氟拉明作为 Dravet 综合征癫痫发作一线附加治疗的疗效和安全性:一项网络荟萃分析。
Epilepsia Open. 2024 Apr;9(2):689-703. doi: 10.1002/epi4.12923. Epub 2024 Mar 1.
5
Methodological review of NMA bias concepts provides groundwork for the development of a list of concepts for potential inclusion in a new risk of bias tool for network meta-analysis (RoB NMA Tool).方法学综述 NMA 偏倚概念为开发新的网络荟萃分析(RoB NMA 工具)偏倚风险工具中潜在概念清单奠定基础。
Syst Rev. 2024 Jan 12;13(1):25. doi: 10.1186/s13643-023-02388-x.
6
Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis.原发性手术治疗晚期上皮性卵巢癌后残余病灶阈值:系统评价和网络荟萃分析。第一部分
Am J Ther. 2023;30(1):e36-e55. doi: 10.1097/MJT.0000000000001584. Epub 2022 Dec 20.
7
Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis.替尔泊肽治疗2型糖尿病患者的疗效和安全性:一项贝叶斯网络荟萃分析。
Front Pharmacol. 2022 Oct 14;13:998816. doi: 10.3389/fphar.2022.998816. eCollection 2022.
8
Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis.局部晚期食管癌患者新辅助放化疗与新辅助化疗疗效的比较:一项网状Meta分析。
EClinicalMedicine. 2021 Nov 6;42:101183. doi: 10.1016/j.eclinm.2021.101183. eCollection 2021 Dec.
9
Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective.迈向欧盟卫生技术评估联合委员会方法与德国卫生技术评估的兼容性:从行业角度进行的系统比较与建议
Eur J Health Econ. 2022 Jul;23(5):863-878. doi: 10.1007/s10198-021-01400-2. Epub 2021 Nov 12.
10
Effectiveness comparisons of various therapies for FIGO stage IB2/IIA2 cervical cancer: a Bayesian network meta-analysis.FIGO 分期 IB2/IIA2 宫颈癌各种治疗方法的有效性比较:贝叶斯网状 Meta 分析。
BMC Cancer. 2021 Oct 6;21(1):1078. doi: 10.1186/s12885-021-08685-9.